Abstracts tagged "autoimmune diseases"

Abstract Number: 1555 • ACR Convergence 2025
Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
Alain Lescoat¹, Virginia Steen², Monica Harding³, John VanBuren³, Brian Skaug⁴, Shervin Assassi⁵, Maureen Mayes⁶, Zsuzsanna McMahan⁷, Elana Bernstein⁸, Flavia Castelino⁹, Lorinda Chung¹⁰, Luke Evnin¹¹, Tracy Frech¹², Jessica Gordon¹³, Faye Hant¹⁴, Laura Hummers¹⁵, Kimberly Lakin¹³, Dorota Lebiedz-Odrobina³, Yiming Luo¹⁶, Ashima Makol¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah¹⁵, Ankoor Shah²¹, Elizabeth Volkmann²², Carleigh Zahn²³ and Dinesh Khanna²⁴, ¹CHU Rennes - University Rennes, Rennes, France, ²Georgetown University School of Medicine, Washington, DC, ³University of Utah, Salt Lake City, UT, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷UT Health Houston, Houston, TX, ⁸Columbia University Irving Medical Center, New York, NY, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Stanford University, Stanford, CA, ¹¹Scleroderma Research Foundation, San Francisco, CA, ¹²Vanderbilt University Medical Center, Nashville, TN, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Medical University of South Carolina, Charleston, SC, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶Columbia University Irving Medical Center, New York, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern University, Chicago, ²⁰University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ²¹Duke University, Durham, NC, ²²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²³University of Michigan, Ann Arbor, ²⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by a wide range of clinical manifestations and available interventions still lack overall efficacy. Limited cutaneous SSc (lcSSc) and…
Abstract Number: 1457 • ACR Convergence 2025
Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
Philip J. Mease¹, Qi Wei², Lawrence Huang³, Jason Hawkes⁴, Clive Liu⁵, Ying Wu⁶, Tony Wang⁷, Anthony Hager⁸ and Jennifer Hadlock³, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Institute for Systems Biology, Seattle, WA, ³Institute for Systems Biology, Seattle, ⁴Oregon Medical Research Center, Portland, OR, ⁵Bellevue Dermatology, Bellevue, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Meyers Squib, Princeton, NJ, ⁸Bristol Myers Squibb, Seattle, WA
Background/Purpose: Real world data from community healthcare systems can provide insights into patient trajectories with psoriasis (PsO) and psoriatic arthritis (PsA): baseline characteristics, patterns of…
Abstract Number: 1282 • ACR Convergence 2025
Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)
Alina-Lucica Boteanu¹, Clara Udaondo², Joan Calzada³, Daniel Clemente Garulo⁴, Juan Carlos Nieto Gonzáles⁵, Eugenia Enriquez⁶, inmaculada Calvo Penades⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, isabel Patora Granados bautista²⁴, Clara Moriano²⁵, Diego Dios¹⁷, Lorena Exposito²⁶, Alicia Garcia²⁷, Laura Martin²⁸, David Fernandez²⁹, Laura Trujillo¹⁴, Anahy Maria Brandy³⁰ and CARLOS GUILLEN-ASTETE³¹, ¹H.U. Ramón y Cajal, Madrid, Spain, ²La Paz University Hospital, Madrid, Spain, ³University Hospital Sant Joan de Deu, Barcelona, Spain, ⁴H.U Niño Jesús, Madrid, Spain, ⁵H.U Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴H.U Toledo, Toledo, Spain, ²⁵Hospital León, LEON, Castilla y Leon, Spain, ²⁶H.U Canarias, Canarias, Spain, ²⁷Rheumatologist, La Laguna, Spain, ²⁸H.R.U Malaga, Malaga, Spain, ²⁹Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³⁰Hospital Germans Trias i Pujol, Badalona, Spain, ³¹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: SLE is a multisystemic autoimmune disease with several manifestations. Childhood-onset SLE (cSLE) has a more severe disease course than adult-onset SLE, with a higher…
Abstract Number: 1152 • ACR Convergence 2025
Cutaneous Panniculitis in Rheumatology: A Descriptive Cohort Study from a Multidisciplinary Experience
Claudia Campos-Fabre¹, Carlota Ureta-Moneva¹, Elena Sendagorta¹, Jose Rodríguez-Gago¹, Maria José Beato¹, Agustin Remesal², Rosa Alcobendas¹, Clara Udaondo¹, Gema Bonilla³, Laura Nuño⁴, Irene Monjo Henry², Carolina Tornero⁵ and Chamaida Plasencia-Rodríguez², ¹La Paz University Hospital, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ⁴Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁵Hospital La Paz, Madrid, Spain
Background/Purpose: Panniculitis refers to inflammatory disorders of subcutaneous fat that pose diagnostic challenges due to nonspecific clinical features and overlapping histopathological patterns. Although it can…
Abstract Number: 0996 • ACR Convergence 2025
Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation
Obinna Ubah, Euan Murray, Stella Priyanka, Julia Martinez Fraile, Andrew Porter, Robert Boyd and Caroline Barelle, Elasmogen Limited, Aberdeen, United Kingdom
Background/Purpose: Despite advances in therapies for chronic autoimmune diseases such as rheumatoid arthritis (RA), significant unmet needs persist, including therapeutic ceiling effects, adverse events, and…
Abstract Number: 0931 • ACR Convergence 2025
Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage
Salvador Campos¹, Sergio Aguilera², Juan Gutiérrez¹, Isabel Castro³, Patricia Carvajal³, Lorena Carvajal¹, Sergio González⁴, Claudio Molina⁵, María-Julieta González⁶ and María-José Barrera⁵, ¹Universidad San Sebastián, Santiago, Region Metropolitana, Chile, ²Clinica Indisa, Santiago, Region Metropolitana, Chile, ³Departamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile, ⁴Escuela de Odontología, Universidad Mayor, Santiago, Region Metropolitana, Chile, ⁵Facultad de Odontología, Universidad San Sebastián, Santiago, Region Metropolitana, Chile, ⁶ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile
Background/Purpose: Primary Sjögren's disease (pSjD) is a systemic autoimmune disease characterized mainly by immune-mediated damage to exocrine glands. Previously, we found decreased expression of ATG5…
Abstract Number: 0898 • ACR Convergence 2025
Distinct B Cell and Plasma Cell Immunosuppression Strategies Eliminate Antigen-Specific Cells of the B Lineage
Carley Tasker¹, Nicholas Giovannone², Nyanza Rothman², Sofia Caruso², Julia Provino², Laura Johnsen², Johanna Napetschnig², Jamie Orengo¹, Christos Kyratsous², Andre Limnander¹, Katherine Cygnar² and Andrew Baik², ¹Regeneron, Tarrytown, NY, ²Regeneron Pharmaceuticals, Tarrytown
Background/Purpose: Development of effective targeting strategies to eliminate sources of antibody production presents utility in the treatment of autoimmune diseases driven by pathogenic autoantibodies. Furthermore,…
Abstract Number: 0888 • ACR Convergence 2025
TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis
Adam S. Weinheimer¹, Olivia Pryor², Catalina Burbano³, Tyler Heath³, Livio Dukaj³, Shoshana M.K. Bloom³, Jackson Lirette³, Rachel Lent³, Prachi Dhanania³, Nicole A. Ladd³, Ryan Kritzer³, Hana Husic³, Shobitha Jillella³, Alexander Cristofaro², Chandan K. Pavuluri³, Jenna LaBelle³, Laurie Barefoot³, Shrikanta Chattopadhyay³, Andrew P. Ferretti³ and Cagan Gurer³, ¹TScan Therapeutics, Boston, MA, ²TScan Therapeutics, Waltham, ³TScan Therapeutics, Waltham, MA
Background/Purpose: Antigen-specific therapies offer a promising approach to selectively modulating autoimmune responses without broad immunosuppression. Strong associations with specific Class I HLA alleles in ankylosing…
Abstract Number: 0494 • ACR Convergence 2025
LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates
Matt McClure¹, Catherine Carriere¹, Kierstin Bell¹, Rex Williams², Geoff Kuesters², Emily Sansevere², Dave Nichols², Arthur Tzianabos² and Jay Rothstein¹, ¹Lifordi Immunotherapeutics, Lebanon, NH, ²Lifordi Immunotherapeutics, Burlington, MA
Background/Purpose: Glucocorticoids (GCs) are the most versatile and efficacious anti-inflammatory drugs rheumatologists have available for patients. Unfortunately, prolonged systemic GC exposure leads to unacceptable toxicities,…
Abstract Number: 0286 • ACR Convergence 2025
Anifrolumab For Treatment Of Refractory Juvenile Dermatomyositis In Adult Patients
Connor Buechler¹ and David Pearson², ¹University of Minnesota, Mendota Heights, MN, ²Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune connective tissue disorder with a chronic, relapsing course that can persist into adulthood. Current therapies exhibit widely variable…
Abstract Number: 0248 • ACR Convergence 2025
Clinical and serological characteristics of anti-Ku autoantibodies in a Hispanic cohort
Emmanuel Dominguez-Chapa¹, Angel Kevin Garza-Elizondo², Karina Deciderio-Pavon³, Rosa Arvizu-Rivera⁴, Jesus Alberto Cardenas-de la Garza⁵, Miguel Villarreal-Alarcón⁶ and Dionicio A. Galarza-Delgado⁷, ¹Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo Leon, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Nuevo León, Mexico, ⁷Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Anti-Ku antibodies are rare myositis-associated antibodies directed against a DNA-binding heterodimer involved in DNA repair. Anti-Ku positivity may be associated with a distinct clinical…
Abstract Number: 0157 • ACR Convergence 2025
Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
Lesley Jackson¹, Nicole Wright², Rahima Begum³, Fazlur Rahman¹, Rena Patel¹, Kenneth Saag⁴, Jeffrey Curtis⁵ and Maria I. ("Maio") Danila⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Tulane University School of Medicine, New Orleans, LA, ³University of Alabama at Birmingham, Birmingham, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Rheumatologists and primary care providers (PCPs) are some of the most trusted clinicians for people living with autoimmune rheumatic diseases (AIRD), and they may…
Abstract Number: 0029 • ACR Convergence 2025
A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing
Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil², Evan Troendle³, Oisin Cappa³, Maite Leonardo⁴, Ana Peñalba⁴, Luis mARTIN pENAGOS⁵, Ligia Gabrie-Rodriguez⁶, Rafael Gálvez Sánchez⁶, Jose Luis Callejas⁷, Belen Sevilla⁸, Diego de Argila⁹, Esther Vicente-Rabaneda⁹, Santos Castañeda¹⁰, David Simpson³, Ricardo Blanco¹¹, Verónica Pulito Cueto¹ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Queens University, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, United Kingdom, ⁴Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁷Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ⁸Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Universitario de la Princesa, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgA vasculitis (IgAV) is a systemic small-vessel vasculitis characterized by immune complex deposition containing aberrantly glycosylated IgA1. While its clinical manifestations are well defined…
Abstract Number: 2460 • ACR Convergence 2025
Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Pablo Martínez Calabuig¹, Jorge Juan Fragío Gil², Roxana González Mazario³, Laura Salvador Maicas⁴, Mireia Sanmartin Martínez⁴, Iván Jesús Lorente Betanzos⁴, Amalia Rueda Cid⁴, Juan José Lerma Garrido⁴, Isabel Martínez Cordellat⁴, Isabel Balaguer Trull⁴, Berta Gómez Correas⁴ and Cristina Campos Fernández³, ¹Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ²Hospital General Universitario, Valencia, Spain, ³Hospital General de Valencia, Valencia, Spain, ⁴Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement and fluctuating activity. Biologic therapies such as Belimumab, Anifrolumab, and Rituximab offer…
Abstract Number: 2658 • ACR Convergence 2025
Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
Hsin-Hua Chen and Wen-Cheng Chao, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM) and obesity due to their beneficial metabolic effects. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].